Moderna has received Health Canada's approval for its respiratory syncytial virus messenger ribonucleic acid (mRNA) vaccine ...

Researchers found that vaccine effectiveness was 80% and 81% against RSV-associated hospitalizations and against RSV-associated critical illness among 28,271 hospitalizations for RSV-like illness ...

New mRNA Vaccine Created to Prevent and Treat ... Big Data, Real World, Multi-State Study Finds RSV Vaccine Highly Effective in Protecting Older Adults Against Severe Disease, Hospitalization ...

The company says it expects the RSV vaccine — called mRESVIA — to be available in early 2025. There are two other vaccines ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

Moderna (MRNA) announced Health Canada has approved mRESVIA for active immunization for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in adults 60 years of ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

Health Canada has approved the vaccine, mRESVIA, for the prevention of lower respiratory tract disease in older adults, the company said.

FDA Approvals and Expansions In May, the FDA approved the mRNA-1345 RSV vaccine (mResvia) from Moderna for people ages 60 and ...

Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...

Moderna Inc.'s stock was higher but off its early highs Thursday, after the company's third-quarter earnings showed an unexpected profit as well as revenue that beat estimates by a wide margin. The ...

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...